Goodwin Procter and Wilson Sonsini Goodrich & Rosati represented MBX Biosciences, Inc. in the offering, and Davis Polk & Wardwell represented the underwriters. MBX Biosciences, Inc....
You must be a Standard 1 Year member to access this content.
Goodwin advised bit.bio on the agreement. BlueRock Therapeutics LP, a wholly owned, independently operated subsidiary of Bayer AG, and bit.bio announced a collaboration and option agreement for...
You must be a Standard 1 Year member to access this content.
Fenwick and Goodwin represented Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry,...
You must be a Standard 1 Year member to access this content.
Cleary Gottlieb represented Takeda in the transaction while Goodwin Procter advised Nimbus Therapeutics. Takeda (TSE:4502/NYSE:TAK) announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Nimbus Therapeutics on the deal. Nimbus Therapeutics announced its Research Collaboration and License Agreement with Eli Lilly and Company for the exclusive and worldwide...
You must be a Standard 1 Year member to access this content.
Goodwin advised Royalty Pharma plc on the deal. Royalty Pharma plc (Nasdaq: RPRX) announced its definitive agreement to acquire a royalty interest in TRELEGY ELLIPTA (Trelegy) from...
You must be a Standard 1 Year member to access this content.
Skadden advised Theravance Biopharma, while Goodwin Procter advised Royalty Pharma on the deal. Willkie Farr & Gallagher advised Innoviva on the sale of its stake in...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised BridgeBio Pharma, Inc. on the deal. BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced its exclusive license agreement wit Bristol Myers Squibb to develop and...
You must be a Standard 1 Year member to access this content.
Johnson Winter & Slattery worked with Moderna’s US lawyers, Goodwin Procter LLP on the matter. Moderna, a pioneer in mRNA vaccines, signed a 10-year strategic deal with...
You must be a Standard 1 Year member to access this content.
Latham and Watkins advised Avery Dennison, while Goodwin Procter advised Charlesbank. Cleary Gottlieb represented Goldman Sachs as financial advisor to Avery Dennison in the transaction. Avery...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised COMPASS Pathways plc on the deal. COMPASS Pathways plc (Nasdaq: CMPS) announced its public follow-on offering of 4,000,000 American Depositary Shares (“ADSs”) representing...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised COMPASS Pathways plc on the deal. COMPASS Pathways plc (Nasdaq: CMPS) announced its public follow-on offering of 4,000,000 American Depositary Shares (“ADSs”) representing...
You must be a Standard 1 Year member to access this content.
